Astrazeneca earnings were $10.2B for the trailing 12 months ending Dec 31, 2025, with 45.4% growth year over year. The latest AZN earnings report on Dec 31, 2025 announced Q4 2025 earnings of $2.3B, down 8.2% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, AZN reported annual earnings of $10.2B, with 45.3% growth.
AZN past earnings growth
How has AZN's earnings growth performed historically?
On AZN's earnings call on Invalid Date, Astrazeneca (NYSE: AZN) reported Q4 2025 earnings per share (EPS) of $1.50, up 54.64% year over year. Total AZN earnings for the quarter were $2.33 billion. In the same quarter last year, Astrazeneca's earnings per share (EPS) was $0.97.
As of the last Astrazeneca earnings report, Astrazeneca is currently profitable. Astrazeneca's net profit (also called net income) for the twelve months ending Dec 31, 2025 was $10.23 billion, a 45.34% increase year over year.
What was AZN's earnings growth in the past year?
As of Astrazeneca's earnings date in Invalid Date, Astrazeneca's earnings has grown 45.37% year over year. This is 91.5 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 136.88%. AZN earnings in the past year totalled $10.23 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.